Theravance Biopharma
TBPH
94 hedge funds and large institutions have $722M invested in Theravance Biopharma in 2014 Q2 according to their latest regulatory filings, with 94 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3% less call options, than puts
Call options by funds: $131K | Put options by funds: $135K
Top Buyers
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$182M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$62.8M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$62.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.3M |
| 5 |
O
OppenheimerFunds
New York
|
+$32.7M |
Top Sellers
TBPH Hedge Fund Activity: Q2 2014 in Review
94 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2014, worth a combined $722M.
Buyers outnumbered sellers: 94 funds opened new TBPH positions and 0 closed out — a net gain of 94 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baupost Group, opening a new position worth an estimated $182M.
- 94 institutional investors held Theravance Biopharma (TBPH) as of Q2 2014, up from 0 in Q1 2014.
- Funds reported $722M of Theravance Biopharma stock for Q2 2014.
- 94 funds opened new Theravance Biopharma positions in Q2 2014 and 0 closed out, a net change of +94 holders.
- The largest Theravance Biopharma buyer in Q2 2014 was Baupost Group, an estimated $182M added.
Based on aggregated 13F filings for Q2 2014.